VRTX Vertex Pharmaceuticals
Nasdaq · SEC CIK 875320 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $158.38M 53 sales by 13 insiders
- Filings on record
- 531 since 2021-07-16, latest 2026-09-10 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| Bozic Carmen | EVP, CMO | — | $11.31M |
| WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| Biller Jonathan | EVP, CLO | — | $4.08M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 621
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-05-01 | 2023-04-27 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $339.08 | -3,317 | 126.7K | -3% | -$1.12M |
| DM | 2023-04-14 | 2023-04-12 | VRTX | SACHS BRUCE I | Dir | S - Sale+OE | $326.73 | -21.3K | 59.6K | -26% | -$6.96M |
| D | 2023-04-14 | 2023-04-13 | VRTX | SACHS BRUCE I | Dir | G - Gift | $0.00 | -1,210 | 40.0K | -3% | $0 |
| D | 2023-04-14 | 2023-04-12 | VRTX | SACHS BRUCE I | Dir | M - OptEx | $72.14 | +21.3K | 62.5K | +52% | +$1.54M |
| M | 2023-04-14 | 2023-04-12 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $326.70 | -7,567 | 42.3K | -15% | -$2.47M |
| M | 2023-04-06 | 2023-04-04 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $315.81 | -522 | 47.3K | -1% | -$164.9K |
| 2023-04-04 | 2023-03-31 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $313.74 | -176 | 7,127 | -2% | -$55.2K | |
| 2023-04-04 | 2023-03-31 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $313.74 | -1,466 | 47.8K | -3% | -$459.9K | |
| 2023-03-28 | 2023-03-24 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $305.38 | -1,768 | 49.6K | -3% | -$539.9K | |
| M | 2023-03-21 | 2023-03-17 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $296.39 | -2,000 | 51.6K | -4% | -$592.8K |
| M | 2023-03-20 | 2023-03-16 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.59 | -2,746 | 49.5K | -5% | -$825.4K |
| M | 2023-03-14 | 2023-03-10+ | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $291.98 | -4,754 | 56.9K | -8% | -$1.39M |
| 2023-02-28 | 2023-02-24 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $289.12 | -13.7K | 48.3K | -22% | -$3.97M | |
| M | 2023-02-28 | 2023-02-27 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $287.48 | -354 | 56.8K | -0.6% | -$101.8K |
| 2023-02-28 | 2023-02-24 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $289.12 | -3,308 | 57.2K | -5% | -$956.4K | |
| 2023-02-28 | 2023-02-24 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $289.12 | -3,970 | 52.0K | -7% | -$1.15M | |
| 2023-02-28 | 2023-02-24 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $289.12 | -3,308 | 63.2K | -5% | -$956.4K | |
| M | 2023-02-28 | 2023-02-27 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $287.55 | -1,207 | 7,528 | -14% | -$347.1K |
| 2023-02-28 | 2023-02-24 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $289.12 | -502 | 8,510 | -6% | -$145.1K | |
| 2023-02-28 | 2023-02-24 | VRTX | Sachdev Amit | EVP, Chief Patient Off | F - Tax | $289.12 | -2,468 | 66.5K | -4% | -$713.5K | |
| 2023-02-28 | 2023-02-24 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $289.12 | -3,308 | 58.1K | -5% | -$956.4K | |
| 2023-02-28 | 2023-02-24 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $289.12 | -3,970 | 36.3K | -10% | -$1.15M | |
| M | 2023-02-28 | 2023-02-27 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $287.51 | -4,238 | 32.0K | -12% | -$1.22M |
| M | 2023-02-28 | 2023-02-27 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $287.47 | -5,034 | 57.8K | -8% | -$1.45M |
| 2023-02-28 | 2023-02-24 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $289.12 | -4,714 | 61.6K | -7% | -$1.36M | |
| 2023-02-28 | 2023-02-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $289.12 | -9,386 | 130.0K | -7% | -$2.71M | |
| M | 2023-02-24 | 2023-02-22 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $294.33 | -2,401 | 66.3K | -3% | -$706.7K |
| 2023-02-22 | 2023-02-17 | VRTX | Sachdev Amit | EVP, Chief Patient Off | F - Tax | $292.85 | -3,498 | 69.0K | -5% | -$1.02M | |
| M | 2023-02-22 | 2023-02-21 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $293.77 | -4,002 | 40.2K | -9% | -$1.18M |
| 2023-02-22 | 2023-02-17 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $292.85 | -3,750 | 44.2K | -8% | -$1.10M | |
| 2023-02-22 | 2023-02-17 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $292.85 | -3,750 | 66.5K | -5% | -$1.10M | |
| 2023-02-22 | 2023-02-17 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $292.85 | -3,750 | 56.0K | -6% | -$1.10M | |
| M | 2023-02-22 | 2023-02-21 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $293.75 | -480 | 60.8K | -0.8% | -$141.0K |
| 2023-02-22 | 2023-02-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $292.85 | -4,498 | 60.9K | -7% | -$1.32M | |
| 2023-02-22 | 2023-02-17 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $292.85 | -3,750 | 61.4K | -6% | -$1.10M | |
| 2023-02-22 | 2023-02-17 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $292.85 | -9,359 | 139.4K | -6% | -$2.74M | |
| M | 2023-02-22 | 2023-02-21 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $293.75 | -2,402 | 68.7K | -3% | -$705.6K |
| 2023-02-22 | 2023-02-17 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $292.85 | -4,498 | 71.1K | -6% | -$1.32M | |
| M | 2023-02-16 | 2023-02-14 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $298.70 | -6,398 | 50.2K | -11% | -$1.91M |
| M | 2023-02-16 | 2023-02-14 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -2,181 | 60.0K | -4% | -$655.2K |
| M | 2023-02-16 | 2023-02-14 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $298.68 | -6,398 | 79.7K | -7% | -$1.91M |
| M | 2023-02-16 | 2023-02-14 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.52 | -320 | 65.7K | -0.5% | -$95.5K |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $296.88 | -7,699 | 70.3K | -10% | -$2.29M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $296.82 | -9,451 | 65.2K | -13% | -$2.81M |
| M | 2023-02-14 | 2023-02-13 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $298.90 | -4,798 | 54.9K | -8% | -$1.43M |
| 2023-02-14 | 2023-02-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $298.26 | -13.3K | 62.1K | -18% | -$3.98M | |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Sachdev Amit | EVP, Chief Patient Off | F - Tax | $296.85 | -7,268 | 72.5K | -9% | -$2.16M |
| M | 2023-02-14 | 2023-02-13 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.99 | -275 | 66.0K | -0.4% | -$82.2K |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $297.02 | -4,372 | 69.0K | -6% | -$1.30M |
| M | 2023-02-14 | 2023-02-13 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $298.92 | -4,887 | 82.0K | -6% | -$1.46M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $296.84 | -9,362 | 86.9K | -10% | -$2.78M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $297.58 | -5,242 | 62.0K | -8% | -$1.56M |
| 2023-02-14 | 2023-02-13 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -113 | 61.9K | -0.2% | -$33.9K | |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $296.84 | -9,362 | 154.7K | -6% | -$2.78M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $296.88 | -7,699 | 65.2K | -11% | -$2.29M |
| DM | 2023-02-08 | 2023-02-06 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $306.00 | -1,304 | 69.9K | -2% | -$399.0K |
| D | 2023-02-08 | 2023-02-06 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $187.53 | +1,304 | 69.9K | +2% | +$244.5K |
| I | 2023-02-03 | 2022-05-17 | VRTX | Sachdev Amit | EVP, Chief Patient Off | G - Gift | $0.00 | -1,672 | 11.1K | -13% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | Sachdev Amit | EVP, Chief Patient Off | A - Grant | $0.00 | +26.4K | 79.8K | +49% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +38.2K | 96.3K | +66% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | A - Grant | $0.00 | +29.3K | 47.1K | +164% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +68.5K | 102.0K | +204% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +30.0K | 53.2K | +130% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +24.3K | 52.3K | +87% | $0 |
| 2023-02-03 | 2023-02-01 | VRTX | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +6,293 | 11.6K | +119% | $0 | |
| M | 2023-02-03 | 2023-02-01 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +76.6K | 68.8K | New | $0 |
| 2023-02-03 | 2023-02-02 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $317.83 | -3,578 | 75.4K | -5% | -$1.14M | |
| M | 2023-02-03 | 2023-02-01 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +5,516 | 9,012 | +158% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +28.5K | 59.8K | +91% | $0 |
| M | 2023-02-03 | 2023-02-01 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +32.6K | 48.5K | +205% | $0 |
| 2023-02-02 | 2023-01-31 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $325.00 | -106 | 38.0K | -0.3% | -$34.5K | |
| D | 2023-02-02 | 2023-01-31 | VRTX | SACHS BRUCE I | Dir | M - OptEx | $72.14 | +1,200 | 42.4K | +3% | +$86.6K |
| D | 2023-02-02 | 2023-01-31 | VRTX | SACHS BRUCE I | Dir | S - Sale+OE | $325.01 | -1,200 | 41.2K | -3% | -$390.0K |
| M | 2023-01-31 | 2023-01-30 | VRTX | CARNEY LLOYD | Dir | S - Sale | $320.52 | -2,700 | 5,474 | -33% | -$865.4K |
| DM | 2023-01-31 | 2023-01-27 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $322.03 | -1,429 | 1,875 | -43% | -$460.2K |
| D | 2023-01-31 | 2023-01-27 | VRTX | Lee Yuchun | Dir | M - OptEx | $72.14 | +1,429 | 3,304 | +76% | +$103.1K |
| 2023-01-27 | 2023-01-25 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $315.05 | -10.0K | 89.6K | -10% | -$3.15M | |
| DM | 2023-01-27 | 2023-01-25+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $316.15 | -8,000 | 1,875 | -81% | -$2.53M |
| DM | 2023-01-27 | 2023-01-25+ | VRTX | Lee Yuchun | Dir | M - OptEx | $72.14 | +8,000 | 5,875 | New | +$577.1K |
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Lee Yuchun | Dir | M - OptEx | $72.14 | +6,129 | 4,004 | New | +$442.1K |
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $312.46 | -6,129 | 3,364 | -65% | -$1.92M |
| DM | 2023-01-19 | 2023-01-17+ | VRTX | Lee Yuchun | Dir | M - OptEx | $72.14 | +4,442 | 2,317 | New | +$320.4K |
| DM | 2023-01-19 | 2023-01-17+ | VRTX | Lee Yuchun | Dir | S - Sale+OE | $312.04 | -4,442 | 1,875 | -70% | -$1.39M |
| 2022-12-08 | 2022-12-06 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +12.8K | 58.0K | +28% | $0 | |
| 2022-11-17 | 2022-11-15 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $308.61 | -34 | 36.1K | -0.1% | -$10.5K | |
| DM | 2022-11-09 | 2022-11-07 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $303.04 | -1,303 | 36.2K | -3% | -$394.9K |
| D | 2022-11-09 | 2022-11-07 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $187.53 | +1,303 | 37.4K | +4% | +$244.4K |
| M | 2022-11-03 | 2022-11-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $312.64 | -320 | 38.2K | -0.8% | -$100.0K |
| 2022-11-03 | 2022-11-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $312.84 | -768 | 38.4K | -2% | -$240.3K | |
| 2022-10-26 | 2022-10-24 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $310.00 | -621 | 4,040 | -13% | -$192.5K | |
| M | 2022-10-20 | 2022-10-18 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.31 | -1,791 | 39.5K | -4% | -$537.9K |
| 2022-09-21 | 2022-09-19 | VRTX | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +5,294 | 5,294 | New | $0 | |
| DM | 2022-08-17 | 2022-08-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $303.93 | -22.2K | 61.6K | -26% | -$6.74M |
| D | 2022-08-17 | 2022-08-15 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +6,571 | 67.5K | +11% | +$1.02M |
| 2022-08-17 | 2022-08-15 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $305.06 | -11.7K | 99.6K | -11% | -$3.57M | |
| M | 2022-08-17 | 2022-08-15 | VRTX | Liu Joy | SVP, GC | S - Sale | $303.90 | -3,747 | 12.3K | -23% | -$1.14M |
| 2022-08-12 | 2022-08-10 | VRTX | Liu Joy | SVP, GC | S - Sale | $300.32 | -36 | 13.4K | -0.3% | -$10.8K | |
| DM | 2022-08-12 | 2022-08-10 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $300.40 | -180 | 60.9K | -0.3% | -$54.1K |
| D | 2022-08-12 | 2022-08-10 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +64 | 61.1K | +0.1% | +$9,956 |
| 2022-08-10 | 2022-08-09 | VRTX | Liu Joy | SVP, GC | S - Sale | $300.00 | -946 | 13.4K | -7% | -$283.8K |
Purchase Sale Sale after option exercise All abbreviations